Open AccessRetrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization
Author(s) -
Justine Alderfer,
Jyoti Aggarwal,
Kim Gilchrist,
J. Alvir,
Joseph Cook,
Sang Hee Park,
Jennifer Stephens
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s319796
Subject(s) - brand names , medicine , market share , advertising , business , marketing
Despite demonstration of bioequivalence of generics to brands and the potential for reduced costs, some patients switch back from a generic to the brand. A prior retrospective analysis suggested that this switchback rate may be lower among patients that had initially switched to authorized generics (AG), often both produced and marketed by the brand company, compared to those initially switched to another generic.